AOD-9604 – 5mg/vial (Research Use Only)

Overview

AOD-9604 is a synthetic fragment of human growth hormone (hGH) that has attracted research interest precisely because of what it lacks: IGF-1 axis interaction. This 16-amino acid C-terminal fragment, originally developed at Monash University, reproduces the lipolytic-relevant region of hGH while published research suggests it does not stimulate insulin-like growth factor-1 production — a distinction that has made it a valuable compound for studying the independent contributions of different hGH domains to metabolic and adipose tissue biology.

What It Is

AOD-9604 is a synthetic 16-amino acid peptide corresponding to residues 177–191 of human growth hormone, with an additional N-terminal tyrosine residue and a disulfide bond between Cys182 and Cys189. Its molecular weight is approximately 1,817 Da. Originally designated ‘Anti-Obesity Drug 9604,’ it was developed at Monash University as part of research programs examining which regions of the hGH molecule are responsible for distinct biological activities.

Research Spotlight

AOD-9604 has been documented in published preclinical research primarily in the context of adipocyte biology and lipid metabolism. In vitro studies have examined AOD-9604’s interactions with beta-3 adrenergic receptors on fat cells, investigating lipolysis stimulation and lipogenesis inhibition mechanisms distinct from those of full-length hGH. Rodent model studies have measured adipose tissue responses at multiple anatomical depots using histological, biochemical, and body composition endpoints.

A critical finding published in the preclinical literature is that AOD-9604 does not appear to interact with the IGF-1 axis in the manner observed with intact hGH — investigators have specifically examined insulin-like growth factor binding protein profiles and IGF-1 serum levels in animal model studies following AOD-9604 administration, with published data suggesting a distinct pharmacological profile. AOD-9604 has also progressed through published clinical pharmacokinetic studies examining its safety profile and plasma half-life, with Phase I and Phase II clinical data published in the scientific literature.

Key Research Applications

• Adipocyte biology and adipose tissue lipolysis/lipogenesis mechanism studies
• Beta-3 adrenergic receptor interaction and fat cell signaling research
• hGH domain-selective activity studies (adipolytic vs. IGF-1-mediated effects)
• Body composition and adipose depot-specific response modeling in rodents
• Lipid metabolism marker studies in diet-induced obesity animal models
• Comparative pharmacology against full-length hGH and other hGH fragments
• Clinical pharmacokinetic reference data support and PK/PD modeling studies
• Metabolic syndrome component research (adiposity, lipid profiles, insulin)

Purity & Quality

Portal to Wellness AOD-9604 is lyophilized to ≥98% purity per supplier specification. The 5mg vial size is well-suited for standard laboratory studies. Disulfide bond integrity is confirmed in the synthesis and verification process.

Competitor Research Notes

AOD-9604 disulfide bond integrity is a key quality marker that standard HPLC purity testing does not fully capture. Researchers should ensure their supplier verifies both mass purity and correct disulfide bond formation via mass spectrometry or specific analytical methods. Misfolded or reduced AOD-9604 will not exhibit expected pharmacological activity in research models.

Technical Specifications

FOR RESEARCH USE ONLY. Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? Browse the Research Hub →